Seawolf Therapeutics debuted Monday with $100 million raised across seed and Series A rounds and a Sanofi licensing pact. CEO Elizabeth Alcamo told Reuters, in a report carried by Boursorama, that more capital would probably be needed before applying to begin human trials.

The Sanofi research collaboration and exclusive license cover bleeding disorders and other undisclosed conditions, Fierce Biotech reported. Seawolf is eligible for up to $1.2 billion in milestones and tiered royalties on resulting sales. The agreement includes an upfront payment, whose size Alcamo declined to disclose to Reuters.

The San Diego biotech’s TRIDENT system uses lipid particles to deliver DNA into cell nuclei, aiming to make cells produce therapeutic proteins. Alcamo told Fierce Biotech the goal is dosing every six or 12 months for patients who need regular biologic infusions.

Versant Ventures led the seed round and also participated in the Series A. MPM BioImpact, Novartis Venture Fund and Eli Lilly were among the other Series A investors, according to Fierce.

Seawolf’s lead program aims to increase muscle and reduce fat and has been tested only in animals, Reuters reported. The company plans to select a drug candidate by late 2027 and apply to begin human trials by the end of 2028.

Sources
1Fierce Biotech: financing breakdown and CEO interview ↗
2Reuters via Boursorama: capital needs and development timeline ↗